Navigation Links
Dendreon Reports Third Quarter 2010 Financial Results
Date:11/3/2010

SEATTLE, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2010. Revenue for the third quarter ended September 30, 2010 was $20.2 million compared to $25,000 for the quarter ended September 30, 2009. Revenue for the nine months ended September 30, 2010 was $23.1 million compared to $80,000 for the nine months ended September 30, 2009.  

Revenue from sales of PROVENGE® (sipuleucel-T) steadily increased month over month from $5.2 million in July, to $7.2 million in August and $7.8 million in September. In addition, revenue for October was approximately $9.5 million.

“We’re pleased with the progress we have made in the first six months of the launch of PROVENGE,” said Mitchell H. Gold, M.D., president and chief executive officer. “We look forward to making PROVENGE available to the many patients who may benefit from it and who have had very few appealing treatment options prior to the FDA approval of PROVENGE.”

Dendreon's total operating expenses for the third quarter of 2010 were $87.7 million compared to $25.8 million in the third quarter of 2009. Dendreon’s total operating expenses for the nine months ended September 30, 2010 were $213.7 million compared to $63.7 million for the same period in 2009. Total operating expenses for the three and nine months ended September 30, 2010 include a charge of $13.3 million for the settlement of litigation. The net loss for the quarter ended September 30, 2010 was $79.3 million, or $0.56 per share, which includes a $0.09 charge for the litigation settlement, compared to $45.6 million, or $0.40 per share for the quarter ended September 30, 2009, which included a non-cash charge associated with the revaluation of warrants of $19.4 million or $0.17 per share. The net loss for the nine months ended S
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
2. Dendreon Statement on CMS National Coverage Analysis
3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
4. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
5. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
6. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
7. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
8. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... July 11, 2014 ... Safety & Health Expo 2014 were a ... to London , plus ... exhibition.          (Logo: ... )      (Photo: ...
(Date:7/10/2014)... July 11, 2014  Major advances in radiation ... are being highlighted in a three-day Oncology Summit ... from 10-12 July, 2014.  Renowned national and international cancer experts ... practices and exchange knowledge on modern technologies making ... efficient. The Summit will address ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Aug. 17, 2011 Reportlinker.com announces that ... in its catalogue: Levosimendan ... http://www.reportlinker.com/p0483048/Levosimendan---Comprehensive-patent-search.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Eliminate unnecessary ... patent information. Pipeline Developer is ...
... 16, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with ... The Journal of the American Medical Association ( ... resulted in significant and sustained reductions in uric acid ...
Cached Medicine Technology:Levosimendan - Comprehensive Patent Search 2Levosimendan - Comprehensive Patent Search 3Levosimendan - Comprehensive Patent Search 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 2Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 3Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 4Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 5Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 6Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 7Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients 8
(Date:7/11/2014)... Williamsburg, VA (PRWEB) July 11, 2014 Riverside ... Continuing Care (CBCC) in Virginia in late 2012 and ... – ChooseHome – to residents throughout the Williamsburg and Newport ... CBCC programs provide services and benefits to independent older adults ... have access to a safety net of continuing care services ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Last ... their staff. Jim Siddons joins the agency as a ... graduated in 1994 with a Bachelor’s Degree in Business ... of industry experience and will manage everything from performance ... for trucking to the specialized needs for those in ...
(Date:7/11/2014)... Europe is one of the largest consumers ... irrigated land area. The agricultural sector is a significant ... 30.0% of the total water use. The scale and ... region, but far from negligible in most northern ones. ... 60.0% of the water use in most countries, while ...
(Date:7/11/2014)... The “Proteomics Market by Technology (Protein Microarray, ... Resonance, X-ray Crystallography) - Instruments, Reagents & Services ... the major market drivers, restraints, and opportunities in ... the World (RoW). , The proteomics market has ... mainly due to the increasing need of proteomic ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually ... namely protective coating, opacity, and coloring. These are water ... color to substances such as paper, paints, plastics, and ... upon application impart color to the substance. Some examples ... and hematite. , The coloring action of pigments is ...
Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 2Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 3Health News:Proteomics Market Worth $20,696.4 Million by 2018 - New Report By MarketsandMarkets 4Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3
... HARRISBURG, Pa., Jan. 3 Consumers who,purchased or ... from,the Schumacher,s Inn in Austin, Potter County, should ... Botulism contamination, Health Secretary Dr. Calvin B.,Johnson said ... the restaurant should,immediately contact the Pennsylvania Department of ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer ... a registration,statement covering the resale of 53,747,555 shares ... and Exchange Commission on January,2, 2008., This ... does not,represent a solicitation or offer to buy ...
... mind can affect the body,s health, researchers say , , THURSDAY, ... say they have prescribed a placebo to a patient during ... A majority of doctors in the study also said they ... accept a mind-body relationship that can affect health, the ...
... faster cancer growth and earlier death, agency says ... studies offer further evidence of the health risks posed ... U.S. officials announced Thursday. , The studies showed that ... the drugs as treatment for chemotherapy-induced anemia died sooner ...
... treated for hypothyroidism aren,t likely to drop pounds with ... the Journal of Pediatrics. The study is the first ... loss in pediatric patients., Parents of overweight children ... request thyroid tests, but, unfortunately, screening for hypothyroidism is ...
... with radiation, finding no raised risk to heart , , ... that a common but controversial treatment for prostate cancer ... of heart problems, as some specialists had feared. ... a combination of testosterone-lowering drugs and radiation therapy appeared ...
Cached Medicine News:Health News:Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Almost Half of Doctors Have Prescribed Placebos 2Health News:FDA Reports New Risks Posed by Anemia Drugs 2Health News:FDA Reports New Risks Posed by Anemia Drugs 3Health News:Thyroid treatment no 'quick fix' for weight loss in children 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: